Form 4: Tandem Diabetes Director Equity Transaction
Statement of Changes in Beneficial Ownership
Director Peyton R. Howell acquired 10,220 restricted stock units and converted 8,759 units into common stock.
Summary
- Director Peyton R. Howell was granted 10,220 restricted stock units (RSUs) on May 20, 2026, vesting on the one-year anniversary.
- Director Howell converted 8,759 previously granted RSUs into common stock on May 21, 2026.
- Following these transactions, the director holds 29,836 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation and equity ownership.
Positives
- Director maintains a significant equity stake of 29,836 shares, aligning interests with shareholders.
Negatives
- None identified.
Risks
- Equity grants are subject to the terms of the 2023 Long-Term Incentive Plan.
Future Outlook
The RSUs granted on May 20, 2026, are scheduled to vest on the one-year anniversary, May 20, 2027, subject to the 2023 Long-Term Incentive Plan.
Industry Context
StockSavvy.ai notes that routine equity grants and vestings for directors are standard corporate governance practices in the medical device sector, reflecting typical long-term incentive compensation structures.
Comparison to Industry Standards
- The use of RSUs as a primary vehicle for director compensation is consistent with industry standards for mid-cap medical technology companies.
- The one-year vesting schedule for director equity is standard practice among peers such as Insulet or Dexcom.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Appointment of Jerilyn Laskie as substitute attorney-in-fact for various directors. | 2026-05-20 | Administrative update to facilitate SEC filing processes. |
Stakeholder Impact
- No material impact on shareholders; reflects standard director compensation.
Next Steps
- Vesting of 10,220 RSUs on May 20, 2027.
Key Dates
| Date | Description |
|---|---|
| 2022-04-19 | Original Power of Attorney dates for various directors. |
| 2026-05-20 | Grant of 10,220 RSUs to Peyton R. Howell. |
| 2026-05-21 | Vesting and conversion of 8,759 RSUs into common stock. |
| 2026-05-22 | Filing date of the Form 4. |
Keywords
Tandem Diabetes Care, TNDM, Form 4, Insider Trading, Equity Compensation, Director Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.